NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 20, No. 9
March 1, 1991
NOTICES

WORLD AIDS FOUNDATION ............................................................... 1
Fogarty International Center
Index: FOGARTY INTERNATIONAL CENTER

NEW WORLD MONKEYS AVAILABLE FOR BIOMEDICAL RESEARCH .................. 1
Public Health Service
Index: PUBLIC HEALTH SERVICE

NATIONAL WORKSHOPS ON "PROTECTION OF HUMAN SUBJECTS" ................. 2
National Institutes of Health
Food and Drug Administration
Index: NATIONAL INSTITUTES OF HEALTH, FOOD AND DRUG ADMINISTRATION

ANNUAL REPORT AND ASSURANCE ON POSSIBLE SCIENTIFIC MISCONDUCT ........ 3
Public Health Service
Index: PUBLIC HEALTH SERVICE

NOTICES OF AVAILABILITY (RFPs AND RFAs)

VACCINE PRODUCTION FACILITY (RFP) ............................................. 4
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES

ROLE OF HERPES SIMPLEX VIRUS IN THE PATHOGENESIS OF ORAL MUCOSITIS ASSOCIATED WITH CANCER CHEMOTHERAPY (RFP) .......................... 4
National Institute of Dental Research
Index: DENTAL RESEARCH

DRUG ABUSE TREATMENT EVALUATION RESEARCH CENTER GRANTS (RFA DA-91-05) 5
National Institute on Drug Abuse
Index: DRUG ABUSE

DRUG DISCOVERY GROUPS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH ALZHEIMER'S DISEASE (RFA AG-91-09) ...................... 7
National Institute on Aging
Index: AGING

MEDICAL INFORMATICS RESEARCH TRAINING (RFA LM-91-01) ..................... 8
National Library of Medicine
Index: NATIONAL LIBRARY OF MEDICINE

EXPLORATORY CENTERS FOR HEALTH BEHAVIOR RESEARCH WITH CHILDREN AND ADOLESCENTS (RFA NR-91-02) .................................................. 10
National Center for Nursing Research
National Institute of Child Health and Human Development
National Institute of Mental Health
Index: NURSING RESEARCH, CHILD HEALTH, HUMAN DEVELOPMENT, MENTAL HEALTH

ONGOING PROGRAM ANNOUNCEMENTS

THE NCI OUTSTANDING INVESTIGATOR GRANT (PA-91-28) .......................... 11
National Cancer Institute
Index: CANCER

ACADEMIC AWARD IN ENVIRONMENTAL/OCCUPATIONAL MEDICINE (PA-91-29) .......... 13
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES

SHORT-TERM TRAINING FOR MEDICAL STUDENTS IN ENVIRONMENTAL/OCCUPATIONAL HEALTH (PA-91-30) ......................................................... 14
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES

ERRATA

CLINICAL TREATMENT AND CORRELATES OF UPPER GI CARCINOMA (RFA CA-91-03) 15
National Cancer Institute
Index: CANCER

PREDOCTORAL FELLOWSHIP AWARDS FOR MINORITY STUDENTS (RFA GM-91-01) .......... 16
National Institute of General Medical Sciences
Index: GENERAL MEDICAL SCIENCES

RESEARCH AND DEMONSTRATION GRANTS RELATING TO OCCUPATIONAL SAFETY AND HEALTH 16
National Institute for Occupational Safety and Health (PA-91-27)
Index: OCCUPATIONAL SAFETY, OCCUPATIONAL HEALTH
NOTICES

WORLD AIDS FOUNDATION

P.T. 44; K.W. 0715008, 0502000

Fogarty International Center

The World AIDS Foundation (WAF), jointly sponsored by the U.S. Department of Health and Human Services and the Institut Pasteur of Paris, France, announces its intent to support research and education relating to AIDS in the developing world. The goal of the WAF is to facilitate information exchange and to assist developing countries to respond to the AIDS pandemic.

The WAF is particularly interested in projects that are catalytic, and, once in place, could have a multiplicative effect. The WAF is specifically interested in supporting:

A) short-term, in-country training for clinicians, allied health professionals, and technicians;

B) fellowships to support training for national experts;

C) development and testing of new concepts and demonstrations for preventing the spread of HIV; and

D) highly focused workshops that enhance the scientific process and transfer knowledge needed in the effort against HIV infections and AIDS.

The limit of any single funding request to the WAF is $200,000.

Application Procedures:

Concept letters and applications may be prepared in either English or French. Applicants should submit concept letters for initial consideration. Following review of concept letters, applicants may be invited to submit complete proposals. The annual deadline for receipt of concept letters is April 1.

Concept letters, full applications, and inquiries concerning the programs of the WAF should be directed to either:

World AIDS Foundation
Assistant Secretary for Health
c/o Director, Fogarty International Center
National Institutes of Health
Building 31, Room B2C39
Bethesda, MD 20892
U.S.A.

or

World AIDS Foundation
c/o Director
Institut Pasteur
28 rue du Docteur Roux
75724 Paris, Cedex 15
FRANCE

NEW WORLD MONKEYS AVAILABLE FOR BIOMEDICAL RESEARCH

P.T. 34; K.W. 0780000

Public Health Service

The Interagency Research Animal Committee, chartered by the U.S. Public Health Service (PHS), supports and coordinates a program with the Pan American Health Organization that makes possible the importation of New World monkeys into the United States for use in biomedical research projects. Transfers are limited to a few species, neither threatened nor endangered. For information on qualifications for participation, species, purchase procedures, and other matters, contact:

NIH GUIDE - Vol. 20, No. 9, March 1, 1991 - Page 1
The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are continuing to sponsor a series of workshops on the responsibilities of researchers, Institutional Review Boards (IRBs), and institutional officials for the protection of human subjects in research. The workshops are open to everyone with an interest in research involving human subjects. The meetings should be of special interest to those persons currently serving or about to begin serving as a member of an IRB. Issues discussed at these workshops are relevant to all other Public Health Service agencies. The current schedule includes the following:

I. MIDEAST WORKSHOP

DATES: March 4-5, 1991

WORKSHOP SITE:
Friday Center
Laurel Hill Parkway
Chapel Hill, NC 27599-1020

SPONSORS:
University of North Carolina at Chapel Hill
300 Bynum Hall
Chapel Hill, NC 27599-4100

Shaw University
118 E. South Street
Raleigh, NC 27611

REGISTRATION CONTACT:
Mr. Al Dawson
Director
Friday Center
Laurel Hill Parkway
C. B. 1020
Chapel Hill, NC 27599-1020
Telephone: (919) 962-1106

TOPIC: "Interpreting the Federal Code for the Protection of Human Subjects"

II. MIDWEST WORKSHOP

DATES: April 11-12, 1991

WORKSHOP SITE:
Ramada Inn, Lakeshore
4900 South Lake Shore Drive
Chicago, IL 60615

SPONSORS:
University of Chicago
970 East 58th Street
Chicago, IL 60637

Chicago State University
95th Street at King Drive
Chicago, IL 60628
ANNUAL REPORT AND ASSURANCE ON POSSIBLE SCIENTIFIC MISCONDUCT

P.T. 34; K.W. 1014006, 1014004

Public Health Service

Effective Date: March 5, 1991

The Public Health Service (PHS) scientific misconduct regulations, 42 CFR 50 Subpart A, "Responsibilities of PHS Awardee and Applicant Institutions for Dealing With and Reporting Possible Misconduct in Science", require institutions report annually to the Office of Scientific Integrity (OSI), about their handling of allegations, inquiries and investigations into possible scientific misconduct, in connection with research for which PHS funds have been requested or received. An annual update of their institutional assurance also must be reported to the OSI.

The annual report forms were mailed by the OSI in December 1990 to the signatory official of 2,600 institutions that had filed an Initial Assurance with OSI for 1990. Most institutions did return the completed form by the January 1991 deadline; others received calls or letters about their reports. However, annual reports for approximately 500 of the smaller institutions have still not been received by the OSI. They are needed now.

An updated, active assurance is a requirement for an institution to remain eligible to apply for or receive grants, fellowships, and cooperative agreements for research funds from the PHS in 1991. The OSI Staff will be updating the approved assurance file in mid-March to change the assurance status to "inactive" for those institutions that have not yet submitted annual reports.

For further information, please call immediately:

Dr. Alan Price, Ms. Carolyn Bowman, or Mr. John Allison
Office of Scientific Integrity
NIH Building 31, Room B1C39
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-2624 (this is not a toll-free number)
FAX: (301) 402-0238
NOTICES OF AVAILABILITY (RFPs AND RFAs)

VACCINE PRODUCTION FACILITY

RFP AVAILABLE: NIAID-91-36

P.T. 34; K.W. 0740075, 1002045

National Institute of Allergy and Infectious Diseases

The Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, requires one Vaccine Production Facility. This contractor must have the professional capabilities and facilities to operate a vaccine production laboratory to prepare live viral, inactivated viral, and subunit candidate vaccines for evaluation in humans. The vaccines must be prepared in accordance with the regulations and guidelines established by the Food and Drug Administration for materials to be tested in humans. Candidate vaccines to be produced include, but are not limited to, influenza viruses, respiratory syncytial virus, parainfluenza viruses, rotaviruses, and subunit preparations from these agents. The offeror's facility must meet requirements listed in the Code of Federal Regulations for an establishment engaged in the preparation of live and inactivated virus vaccines licensed for human use by the Office of Biologics and provide adequate documentation of such qualifications. If not in full compliance, the offeror must describe what efforts have been made to bring the facility into compliance. The offeror is subject to inspection under the "Good Laboratory Practices Act" and the "Good Manufacturing Act." It is expected that the contract will have a five (5) year period of performance. Any responsible offeror may submit a proposal, which will be considered by the Government.

The issuance date of the RFP will be on March 11, 1991 and proposals will be due by the close of business on April 26, 1991.

Requests for the RFP must be directed to:

Merilee Rahe-Stoline
Contract Management Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Control Data Building, Room 326P
Bethesda, MD 20892

Please provide this office with two self-addressed mailing labels. This advertisement does not commit the Government to award a contract.

ROLE OF HERPES SIMPLEX VIRUS IN THE PATHOGENESIS OF ORAL MUCOSITIS ASSOCIATED WITH CANCER CHEMOTHERAPY

RFP AVAILABLE: NIH-NIDR-2-91-5R

P.T. 34; K.W. 0745005, 0740012, 0755015

National Institute of Dental Research

The National Institute of Dental Research (NIDR) has a requirement to study the role of herpes simplex virus (HSV) in the pathogenesis of oral mucositis associated with intensive chemotherapy, and to determine whether the antiviral agent acyclovir can reduce the incidence and severity of mucositis in severely immunocompromised patients. The study will consist of a double-blind, placebo-controlled trial of daily oral acyclovir for the prevention of HSV infection and mucositis in HSV-seropositive patients undergoing intensive chemotherapy for the treatment of leukemias or lymphomas. At the completion of this two-year study, an analysis will be made of the severity and frequency of oral ulcerations and the association of HSV culture/antigen-positive lesions in patients on acyclovir and those on placebo. If the study demonstrates that herpes simplex virus is involved in the pathogenesis of oral mucositis and that acyclovir can reduce the frequency and/or severity of mucositis, then an informed recommendation can be made that all HSV seropositive patients undergoing intensive chemotherapy for acute leukemia or lymphoma receive routine prophylactic acyclovir therapy for each course of chemotherapy.

The NIDR expects to make one award from this solicitation.

RFP NIH-NIDR-2-91-5R will be available on or about March 18, 1991, with proposals due on or about April 30, 1991.
The RFP package will be available upon written request to:

Marilyn R. Zuckerman, Contracting Officer
Contract Management Section, NIDR
National Institutes of Health
Westwood Building, Room 521
5333 Westbard Avenue
Bethesda, MD 20892

DRUG ABUSE TREATMENT EVALUATION RESEARCH CENTER GRANTS

RFA AVAILABLE: DA-91-05
P.T. 04; K.W. 0404009, 0795005

National Institute on Drug Abuse
Application Receipt Date: May 22, 1991

PURPOSE

The purpose of this initiative is to establish and support Centers to conduct interdisciplinary research on the effectiveness of drug abuse treatment.

RESEARCH OBJECTIVES

The Abuse Treatment Evaluation Research Center Grant Program is designed to complement the investigator initiated research grants program of the National Institute on Drug Abuse (NIDA) by providing long-term support for interdisciplinary evaluative research on drug abuse treatment. The program is intended to attract investigators in the behavioral, social, and biomedical sciences to conduct evaluative research on the treatment of drug abuse, and to provide a stable environment for such persons to engage in treatment research. A Center is expected to become a significant regional or national research resource. Centers funded under this announcement will conduct treatment evaluation research and participate actively in and cooperate with NIDA's programmatic efforts to systematically review, coordinate, and integrate research on treatment populations process, and outcomes.

A variety of designs and research strategies may be employed to evaluate existing treatment programming and related interventions. Both field studies and controlled (randomized) studies may be used, as well as secondary analyses to investigate issues of interest to treatment evaluations. Areas for investigation potentially include comparative effectiveness of treatment program types for well-defined client groups, treatment process, the structure of treatment, studies of specific modalities, outreach, differential attractiveness of treatment, client-treatment matching, the role of non-treatment factors, correctional treatment, treatment of drug abuse in primary health care delivery systems, effectiveness of alternative treatments, (i.e., not designed primarily for drug abusers) treatment improvement, treatment for specific drugs of abuse, aftercare and relapse prevention, treatment careers, and cohort-based studies of long-term outcomes. Methodologically oriented studies may also be appropriate activities for the Center under this program.

SPECIAL IMPLEMENTATION OF ADAMHA POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS

Applications/proposals for ADAMHA grants and cooperative agreements are required to include both women and minorities in study populations for clinical research, unless compelling scientific or other justification for not including either women or minorities is provided. This requirement is intended to ensure that research findings will be of benefit to all persons at risk of the disease, disorder, or condition under study. For the purpose of these policies, clinical research involves human studies of etiology, treatment, diagnosis, prevention, or epidemiology of diseases, disorders or conditions, including but not limited to clinical trials; and minorities include U.S. racial/ethnic minority populations (specifically: American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, and Hispanics).

ADAMHA recognizes that it may not be feasible or appropriate in all clinical research projects to include representation of the full array of U.S. racial/ethnic minority populations. However, applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups.
Applications should include a description of the composition of the proposed study population by gender and racial/ethnic group, and the rationale for the numbers and kinds of people selected to participate. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects.

Applications should incorporate in their study design gender and/or minority representation appropriate to the scientific objectives of the work proposed. If representation of women or minorities in sufficient numbers to permit assessment of differential effects is not feasible or is not appropriate, the reasons for this must be explained and justified. The rationale may relate to the purpose of the research, the health of the subjects, or other compelling circumstances (e.g., if in the only study population available, there is a disproportionate representation in terms of age distribution, risk factors, or incidence/prevalence of one gender/minority/majority group). If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If gender and/or minority representation/justification are judged to be inadequate, reviewers will consider this as a deficiency in assigning the priority score to the application.

APPLICATION PROCEDURES

Applicants must use the standard PHS 398 (rev. 10/88) grant application form. When applying, type in item 2 of face page of PHS 398, the name of this announcement: "Drug Abuse Treatment Research Center Program, RFA DA-91-05." Application kits are available from university grant offices and from the Division of Research Grants, National Institutes of Health, Westwood Building, Room 240, 5333 Westbard Avenue, Bethesda, Maryland 20892; Telephone (301) 496-7441.

Applicants must affix the RFA label available in the PHS 398 to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review.

The original and six (6) copies of the application must be submitted to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**

ELIGIBILITY

Applications for research grants may be made by any public or private non-profit or for-profit institutions such as universities, colleges, and hospitals. Women and minority investigators are encouraged to apply.

REVIEW PROCESS AND CRITERIA

The Division of Research Grants, NIH, serves as a central point for receipt of applications for most discretionary HHS grant programs. Applications received under this announcement will be assigned to an initial review group (IRG) convened by NIDA. The IRG will review the applications for scientific and technical merit. Notification of the review recommendations will be sent to the applicant after the initial review. Applications will receive a second-level review by the National Advisory Council on Drug Abuse, whose review may be based on policy considerations as well as scientific merit. Only applications recommended for approval by the Council may be considered for funding.

AWARD CRITERIA

Applications recommended for approval by the National Advisory Council on Drug Abuse will be considered for funding on the basis of overall scientific and technical merit of the Center proposal as determined by peer review, appropriateness of budget estimates, NIDA program needs and balance, NIDA policy considerations, adequacy of provisions for the protection of human subjects, and availability of funds.

AVAILABILITY OF FUNDS

In fiscal year 1991, an estimated $2 million will be available to support new grants under this announcement. The actual amount of funding available will depend on appropriated funds and program priorities at the time of award.

NIH GUIDE - Vol. 20, No. 9, March 1, 1991 - Page 6
INQUIRIES

Prospective applicants may obtain additional information regarding the development of Drug Abuse Treatment Evaluation Research Center grant applications and advice regarding the feasibility/appropriateness of such applications by contacting:

Frank M. Tims, Ph.D.
Deputy Chief, Treatment Research Branch
Division of Clinical Research
National Institute on Drug Abuse
Parklawn Building, Room 10A-30
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4060

For fiscal and administrative matters, contact:

Grants Management Branch
National Institute for Drug Abuse
Parklawn Building, Room 8A54
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-6710

This program is described in the Catalog of Federal Domestic Assistance No. 13.279. Grants will be awarded under the authority of Sections 301 and 515 of the Public Health Service Act, as amended (42 USC 241 and 42 USC 290), and administered in accordance with the PHS Grants Policy Statement and Federal Regulations at 42 CFR Part 52, and 45 CFR Part 74. This program is not subject to the Intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

DRUG DISCOVERY GROUPS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH ALZHEIMER'S DISEASE

RFA AVAILABLE: AG-91-09

P.T. 34; K.W. 0715180, 0740020, 0755025

National Institute on Aging

Application Receipt Date: May 21, 1991
Letter of Intent Receipt Date: April 1, 1991

BACKGROUND

The National Institute on Aging (NIA) invites Program Project applications (P01) for the establishment of Drug Discovery Groups for the Treatment of Cognitive Impairment Associated With Alzheimer's Disease. The U.S. Congress, as part of the Fiscal Year 1991 appropriation, has mandated that NIA "explore new treatment and management methods, including testing promising drugs, such as nerve growth factor and acetyl carnitine, that could safely and effectively slow or reverse the symptoms of Alzheimer's disease."

RESEARCH OBJECTIVES AND SCOPE

The objective of this solicitation is to stimulate multi-center multi-disciplinary preclinical research in the design, development and testing of novel compounds aimed at slowing, halting, or, if possible, reversing the progressive decline in cognitive function in Alzheimer's disease victims. This initiative is intended to stimulate basic research and development efforts which go beyond those already underway or likely to be undertaken by pharmaceutical firms in the foreseeable future. Compounds are needed to correct or improve the functioning at various sites along the signal transduction pathway; e.g. receptors, channels, membrane, second and third messenger, phosphorylation, and signal amplification stages. The discovery of compounds and treatments should be aimed to ameliorate fundamental processes of the neural dysfunction and cell death associated with the disease. The aim is to encourage innovative approaches to the treatment of AD.

MECHANISM OF SUPPORT

Awards will be made as Program Projects (P01). Funding of at least 3 awards is anticipated. Each award is limited to $750,000 total cost per year. The amount spent will be dependent on the continuing availability of funds for
this purpose and the quality and diversity of approved applications. The start date will be on or before September 30, 1991.

APPLICATION AND REVIEW PROCEDURES

In preparing applications, instructions for PHS Form 398 (10/88 revision, reprinted 9/89), supplemental information available from NIA program staff, and additional instructions included in the full RFA should be used. Proposals judged by staff to be nonresponsive to the RFA will be administratively withdrawn and returned to the applicant without review. Responsive proposals may then receive a preliminary review by a subcommittee of the review panel to establish those applications deemed to be competitive. Those judged noncompetitive will be so designated, and an abbreviated summary statement noting the major deficiencies will be sent to the principal investigator. Applications judged to be competitive will be given full review by a special review group convened by NIA. Following review by the initial review group, the applications will be considered by the National Advisory Council on Aging.

Applicants should obtain the full RFA and supplemental information and discuss their plans with and direct any other inquiries to:

Neil Buckholtz, Ph.D.
NIA, NIA, NIH
Building 31, Room 5C35
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-9350
FAX: (301) 496-1494

Inquiries regarding fiscal matters may be addressed to:

Mr. Joseph Ellis
Grants Management Officer
National Institute on Aging
Building 31, Room 5C07
Bethesda, MD 20892

Although not a prerequisite for applying, potential applicants are encouraged to submit to Dr. Buckholtz, at the address indicated above, a non-binding letter of intent to apply by April 1, 1991. Applications must be complete and received by May 21, 1991.

MEDICAL INFORMATICS RESEARCH TRAINING

RFA AVAILABLE: LM-91-01

P.T. 22; K.W. 1004017, 1004000, 0720005, 0710030

National Library of Medicine

Letter of Intent Receipt Date: May 1, 1991
Application Receipt Date: June 10, 1991

PURPOSE

The National Library of Medicine (NLM) invites training grant applications in a single competition for predoctoral and postdoctoral research training in medical informatics. Applications may be for the creation of new training centers or for the renewal of existing NLM-supported training programs. This training will help meet a growing need for qualified, talented investigators, well prepared to address information problems in health care, health professional education, and biomedical research.

Applications must clearly indicate that the primary intent of the program is preparation for an academic career in Medical Informatics. Applications must describe the process by which trainees will become familiar with the many relevant disciplines. To prepare trainees for research careers in a demanding research environment, the sponsorship of a research-oriented, academic health sciences institution is critical. It is expected that the core of training will emphasize the synthesis, organization, retrieval, and effective management of knowledge. The curricula should be inter-disciplinary by including topics in medicine and the biological sciences, the cognitive sciences, information science, and computer science. Training sites must offer an excellent setting for instruction, involvement in important health computer science research, and opportunities for meaningful trainee involvement in such research.
OBJECTIVES AND SCOPE

In addition to the general goal of assisting in the education of persons to be able to take academic positions to conduct research and teach medical informatics, several more specialized additions to the training programs are likely to become available during the next few years to enhance research training. Grants approved in the FY 1991 competition. Consequently, NLM invites applicant institutions to include their plans for such possible enhancements within the application. Some potential enhancement areas (described in the full RFA) are high performance computing and communication, biotechnology, cancer, and information systems. Dental informatics is another area for which additional training slots may become available in the future.

MECHANISM OF SUPPORT

This RFA will use the T15 grant mechanism. NLM plans to make available approximately $3 million for this program in FY 1992. It is expected that six to ten training grants will be awarded; however, actual award of grants pursuant to this RFA is necessarily contingent upon receipt of funds appropriated for this purpose. These awards are authorized by the Medical Library Assistance Act and are not part of the National Research Service Awards Program of the Public Health Service. Prior to initial scientific merit review, a triage mechanism may be employed to screen out applications that are clearly noncompetitive or nonresponsive to the RFA. Such applications would be returned to the applicant.

APPLICATION SUBMISSION

Letter of Intent: Prospective applicants are asked to submit by May 1, 1991, a letter of intent that includes a descriptive title, the name and address of the Principal Investigator, the names and addresses of any other key investigators, and any other participating institutions.

Application form PHS-398 (rev. 10/88) must be used in applying. To identify responses to this announcement, check "yes" and type the RFA number and title [RFA LM-91-01, MEDICAL INFORMATICS RESEARCH TRAINING] in item 2 on page 1 of the grant application. The RFA label provided with the instructions must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of your application such that it may not reach the review committee in time for review.

The completed original application and six (6) copies must be mailed to:

Division of Research Grants
National Institute of Health
Westwood Building, Room 240
Bethesda, MD 20892XX

Applications must be received by June 10, 1991. Applications received after that date will be returned to the applicant. The review process will be completed in October 1991. Funding around July 1, 1992 is anticipated.

INQUIRIES

A more detailed RFA may be obtained from:

Roger W. Dahlen, Ph.D.
Chief, Biomedical Information
Support Branch
Extramural Programs
National Library of Medicine
8600 Rockville Pike
Building 38A, Room 5S522
Bethesda, MD 20894
Telephone: (301) 496-4221
FAX: (301) 402-0421

For fiscal and administrative matters, contact:

Ruth Bortz
National Library of Medicine
8600 Rockville Pike
Building 38A, Room 5S522
Bethesda, MD 20892
Telephone: (301) 496-4253
EXPLORATORY CENTERS FOR HEALTH BEHAVIOR RESEARCH WITH CHILDREN AND ADOLESCENTS

RFA AVAILABLE: NR-91-02

P.T. 34, AA; K.W. 0404000, 0715020, 0745035

National Center for Nursing Research
National Institute of Child Health and Human Development
National Institute of Mental Health

Letter of Intent Receipt Date: April 15, 1991
Application Receipt Date: May 20, 1991

PURPOSE

The National Center for Nursing Research (NCNR), the National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH) invite applications from interested institutions to establish multidisciplinary exploratory centers to investigate health behavior development in children and adolescents (ages 8-18). It is anticipated that approximately 6 exploratory centers will be funded.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This RFA, "Exploratory Centers for Health Behavior Research with Children and Adolescents," is related to the priority area of the development of several health promotion behaviors. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (Telephone 202-783-3238).

BACKGROUND

Recent reports highlight the significance of behaviors relating to diet, physical activity, alcohol and tobacco use, injuries, and sexual behaviors that begin in childhood and adolescence, compromise health in the short term and have major long-range implications for the onset of chronic disease including cardiovascular disease and cancer. This RFA seeks empirically-based multidisciplinary research that will form the foundation for biomedical, behavioral and nursing interventions in health promotion and disease prevention, and facilitate health-enhancing patterns of behavior in children and adolescents.

SPECIFIC OBJECTIVES AND AREAS OF INTEREST

Applicants are invited to apply for support of projects to address issues including but not limited to:

A Behavioral Epidemiology-Identification and Distribution of Behavioral Risk Factors.
B Establishment, Change and Maintenance of Health Related Behaviors.
C Basic Behavioral Biological Mechanisms.

ELIGIBILITY

Institutions or consortia of institutions are eligible to apply if they have at least two Principal Investigators with any PHS agency or comparable peer reviewed research project (RO1) grants that are currently active in health and behavior research.

MECHANISM OF SUPPORT

The support mechanism for this RFA is the Exploratory Center Grant (P20). The Exploratory Center Grant consists of (1) an administrative and planning core providing administrative, coordinating, research planning, logistical, and/or methodological (e.g., research design, data analysis) support and (2) small-scale studies. The initial award period is for three years, and the award may not be renewed. Grants will be administered in accordance with the PHS Grants Policy Statement (10/01/90).

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be
METHOD OF APPLYING

Prior to submission of the formal application, consultation with NCNR, NICHD and/or NIMH concerning the technical and substantive aspects of preparing the application is recommended. Copies of the complete RFA can be obtained from the program staff listed below:

Direct inquiries to:

NCNR
Sharlene M. Weiss, PhD, RN
Chief, Health Promotion/Disease Prevention Branch, NCNR, NIH
9000 Rockville Pike
Building 31, Room 5B09
Bethesda, MD 20892
Telephone: (301) 496-0523

NICHD
Peter Scheidt, MD, MPH
Medical Officer
Human Learning and Behavior Branch, NICHD, NIH,
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-6591

NIMH
Leonard Mitnick, Ph.D.
Chief, Basic Prevention and Behavioral Medicine Research Branch, NIH
Room 11C-06
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4337

ONGOING PROGRAM ANNOUNCEMENTS

THE NCI OUTSTANDING INVESTIGATOR GRANT

PA: PA-91-28
P.T. 34; K.W. 0715035, 0710030
National Cancer Institute
Application Receipt Date: June 1, 1991

SUMMARY AND PURPOSE

The National Cancer Institute (NCI) will continue to accept new applications for the Outstanding Investigator Grant (OIG), as well as competing continuation applications from currently funded OIG recipients in the fifth year of the initial award period. The purpose of the OIG is to encourage investigators to continue or embark on projects of unusual potential in cancer research. Emphasis will be placed on evidence of recent substantive contributions (i.e., seminal ideas and innovative approaches to resistant problems) and the potential for continued work of high caliber.

This announcement significantly modifies available applicable guidelines for the OIG. Special attention should be given to the requirements for "Eligibility" and to the "General Requirements" for preparation of new and competing continuation applications as noted below.

ELIGIBILITY

Applications may be submitted only by domestic institutions on behalf of investigators who have recently demonstrated outstanding research productivity for at least five years. There are no age restrictions. Only United States citizens, nationals or permanent residents may be presented as candidates for this grant.

Applications will be accepted by the NCI only when they are cancer-related as defined by the Division of Research Grants (DRG) grant referral guidelines. Investigators whose current research support is derived predominantly from sources other than the NCI may not be eligible as OIG awardees. As a general rule, investigators will be allowed to consolidate ONLY NCI supported active cancer-related peer reviewed grants into the OIG research effort. In this regard applicants are encouraged to discuss their research objectives with appropriate NCI officials before applying.
The OIG Principal Investigator is required to commit 75 percent of his or her
time and effort to cancer research supported by the OIG, and the institution
sponsoring the OIG application is required to commit itself to providing 25
percent of the Investigator's salary support. However, the NCI will entertain
requests, on a case-by-case basis, for time and effort commitments of less
than 75 percent (with a proposed minimum of 50 percent) to the OIG project
based upon allowable retention of other ongoing peer reviewed grants.

Applications that do not meet all of the above eligibility criteria or that
have not had approval from the NCI as exceptions to the above criteria will be
returned to the applicant.

GENERAL REQUIREMENTS

New (Type 1) and competing continuation (Type 2) OIG applicants will be
required to provide a detailed ("evaluable") proposal emphasizing his/her
accomplishments prior to (Type 1) and during (Type 2) the first grant period
and a detailed description of the activities to be supported under the next
competing award period. The budget request must be in specific terms and a
zero-based budget should be developed to assist reviewers in making explicit
budget recommendations.

REVIEW PROCEDURES

Applications will be assigned to an appropriate subset of a nationwide panel
of recognized cancer investigators convened by the Division of Extramural
activities, NCI and reviewed for scientific and technical merit. Following
review by the initial review group, the applications will receive a
second-level review by the National Cancer Advisory Board (NCAB) prior to a
final funding decision by the NCI.

HOW TO APPLY

- The date of receipt of all OIG applications, including competing
  continuation applications has been changed to June 1 of each year.
  They will be processed for review at the earliest possible meeting
  of the NCAB.

- Applications for this award should be made on Form PHS 398 (rev.
  10/88) in accordance with instructions in this Announcement. These
  forms are available at most academic or research institutional
  business offices and from the Office of Grants Inquiries, Division
  of Research Grants, National Institutes of Health, Room 449
  Westwood Building, 5333 Westbard Avenue, Bethesda, Maryland 20892.

- The title "NCI OUTSTANDING INVESTIGATOR GRANT, PA-91-28" must be
typed in section 2 on the first page of the application.

- A letter indicating clear and continual institutional commitment by
  the Institution to the applicant must accompany the application in
  order for the NCI to begin the review process.

- Applications must be accompanied by a curriculum vitae and a
  complete bibliography. Abbreviated curricula vitae of all
  professional persons (doctoral level or equivalent) listed on the
  personnel page should be included. Reprints of no more than five
  publications may be submitted. For a new application that proposes
  primarily the consolidation of existing NCI-supported research
  grants, the prose portion may not exceed ten typewritten pages.
  For these applications, detailed descriptions of methods are not
  required because the evaluation of the new OIG application will be
  based mostly on the applicant’s track record in the context of
  current peer-reviewed support. However, these new applications
  must outline the main objectives to be pursued and discuss the
  significance of the research. When objectives are proposed that
  are outside the context of current peer-reviewed activities,
  portions of the application addressing those aims should be written
  in more detail. Therefore, for applications proposing new research
  areas, and for competing renewal applications, up to 18 pages of
  prose are allowable.

- The applicant investigator and his/her institution must present a
  workable plan for consolidation of the applicant’s current research
  support and conversion of staff and facilities to be supported by
  the OIG. This must be submitted as a separate section of the grant
  application immediately following the budget section.
The original and six legible copies of the application should be submitted to DRG, NIH, as directed in the instructions of the grant application.

INQUIRIES

All potential applicants of this award are advised that the full text of this Program Announcement, containing currently applicable guidelines, is now available and should be requested prior to submitting an application for the June 1, 1991 receipt date.

Please direct inquiries for further information on application development to:

Barbara S. Bynum
Director
Division of Extramural Activities
National Cancer Institute
Building 31, Room 10A03
Bethesda, MD 20892
Telephone: (301) 496-5147

For fiscal and administrative matters, contact:

Crystal Elliott
Grants Management Specialist
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD 20892
Telephone: (301) 496-7800 x19

Budget request should justify each item for which support is requested and should not be presumed to include all funds currently available to the Principal Investigator under active grant awards.

ACADEMIC AWARD IN ENVIRONMENTAL/OCCUPATIONAL MEDICINE

PA: PA-91-29
P.T. 34; K.W. 0725020, 0725000, 0720005
National Institute of Environmental Health Sciences
Application Receipt Date: June 1, 1991

The National Institute of Environmental Health Sciences (NIEHS) announces its second national competition for Environmental/Occupational Medicine Academic Awards, which first appeared in the NIH Guide, Vol. 19, No. 8, February 23, 1990, Page 9. The award will have the dual purpose of improving the quality of environmental/occupational medicine curricula and of fostering graduate research careers in environmental/occupation medicine. Each school of medicine or osteopathy in the United States and its possessions or territories is eligible to compete for Environmental/Occupational Medicine Academic Award for a project period that does not exceed five years and, if successful, to receive the Award once only. The number of new awards made each year will depend on the availability of funds.

For the purposes of the Environmental/Occupational Medicine Academic Award, the term environmental/occupational medicine refers to the area of medicine concerned with the development of knowledge and the application of knowledge directed at the diagnosis, treatment, and prevention of adverse human health effects from environmental/occupational exposures to toxic agents. This includes adverse health effects in infants, children, and adults who are at risk of developing such health problems and the reduction of preventable complications or disability in persons of all ages who have already developed such diseases.

NIEHS initiated the Environmental/Occupational Medicine Academic Award Program to provide a stimulus for development of an environmental/occupational medicine curriculum in those schools that do not have one and to strengthen and improve the environmental/occupational medicine curriculum in schools that do. Awards provide support to applicant faculty members for their educational development and for implementation or expansion of the curriculum in environmental/occupational medicine.
HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This Program Announcement, Academic Award in Environmental/Occupational Medicine, is related to the priority area of environmental health. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (Telephone 202-783-3238).

Applications must be received by June 1, 1991, for review at the January meeting of the National Environmental Health Sciences Advisory Council. Awards will be made with a beginning date of July 1, 1992. Copies of the Program Guidelines are currently available from:

Annette Kirshner, Ph.D.
Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institute of Health
P. O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-0488

For fiscal and administrative matters, contact:

David L. Mineo
Grants Management Officer
Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institutes of Health
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373

The programs of the National Institute of Environmental Health Sciences are identified in the Catalog of Federal Domestic Assistance, Number 93.894. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to review by a Health Systems Agency.

SHORT-TERM TRAINING FOR MEDICAL STUDENTS IN ENVIRONMENTAL/OCCUPATIONAL HEALTH

PA: PA-91-30
P.T. 34; K.W. 0725020, 0725000, 0720005
National Institute of Environmental Health Sciences

Application Receipt Date: May 10, 1991

The purpose of this second announcement, which first appeared in the NIH Guide, Vol. 19, No. 9, March 2, 1990, Page 10, is to solicit applications for short-term training of medical students in disciplines related to environmental and occupational medicine. Two types of mechanisms are available.

Medical schools at which there is a currently active National Institute of Environmental Health Sciences (NIEHS) Institutional Training Grant (T32) may submit a supplemental application to support 3-5 medical students for summer or off-term research. The period of support may not exceed three months. Requests for short-term training may be submitted only at the time of competitive renewal.

Medical schools that do not currently have an NIEHS Institutional Training Grant but do have ongoing basic and/or clinical research activities in areas related to environmental/occupational health may apply for a National Research Service Award for Short-Term Training (T35) to support 3-5 students per year as described above.
HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This Program Announcement, Short-Term Training for Medical Students in Environmental/Occupational Health, is related to the priority area of environmental health. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (Telephone 202-783-3238).

For additional information and special instructions, contact:

Annette Kirshner, Ph.D.
Scientific Programs Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institute of Health
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-0488

For fiscal and administrative matters, contact:

David L. Mineo
Grants Management Officer
Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
National Institutes of Health
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373

ERRATA

CLINICAL TREATMENT AND CORRELATES OF UPPER GI CARCINOMA

RFA: CA-91-03

P.T. 34; K.W. 0715035, 0705025, 0745070

National Cancer Institute

Letter of Intent Date: February 25, 1991
Application Receipt Date: April 8, 1991

The Division of Cancer Treatment of the National Cancer Institute would like to clarify Request for Applications (RFA) CA-91-03 with regard to appropriate upper gastrointestinal (GI) tumor sites. This RFA titled "Clinical Treatment and Correlates of Upper GI Carcinoma" was published December 28, 1990. Carcinoma of the upper GI tract is now defined to include "pancreatic carcinoma" in addition to esophagus and stomach carcinomas. The RFA invites research grant applications (R01) from interested investigators to assess new clinical correlates and develop new treatment modalities in upper gastrointestinal carcinoma.

Written or telephone inquiries concerning the objectives and scope of this RFA or inquiries about whether or not specific research would be responsive are encouraged and should be directed to Ms. Diane Bronzert at the address below.

Ms. Diane Bronzert
Program Director
Cancer Therapy Evaluation Program
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 734
Bethesda, MD 20892
Telephone: (301) 496-8866
FAX: (301) 496-9384
For fiscal and administrative matters, contact:

Mary Niemiec
DCT Grants
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 242
Bethesda, MD 20892
Telephone: (301) 496-7800

PREDOCTORAL FELLOWSHIP AWARDS FOR MINORITY STUDENTS

RFA: GM-91-01
P.T. 22, FF; K.W. 072005, 1014002

National Institute of General Medical Sciences

Application Receipt Date: May 10, 1991

The Eligibility Requirements as printed in the NIH Guide for Grants and Contracts on February 15, 1991, Vol. 20, No. 7, should be corrected to read:

ELIGIBILITY REQUIREMENTS

An applicant must currently be enrolled in a Ph.D. or M.D./Ph.D. graduate program in the biomedical sciences, or have been accepted by and agreed to enroll in such a graduate program the following academic year.

Eligibility for these awards is limited to students who are U.S. citizens, non-citizen nationals, and permanent residents from ethnic/racial groups that are underrepresented in research in the biomedical sciences. For the purpose of this announcement, underrepresented minority students are defined as individuals belonging to a particular ethnic or racial group which has been determined by the applicant's graduate institution to be underrepresented in biomedical or behavioral research. In making these awards, the NIH will give priority consideration to applications from Black, Hispanic, Native American, and Pacific Islander and other ethnic or racial group members who have been found to be underrepresented in biomedical or behavioral research nationally.

RESEARCH AND DEMONSTRATION GRANTS RELATING TO OCCUPATIONAL SAFETY AND HEALTH

PA: PA-91-27
P.T. 34; K.W. 0725020, 0403004, 0715027

Centers for Disease Control
National Institute for Occupational Safety and Health

This Program Announcement was published in the NIH Guide for Grants and Contracts on February 22, 1991, Vol. 20, No. 8., and contained an incorrect PA number. The corrected PA number is PA-91-27. Applications submitted in response to this Program Announcement must insert the title of this announcement and PA-91-27 on line 2 of the application face page.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:

5333 Westbard Avenue
Bethesda, Maryland 20816